Ascletis Pharma Inc.

home

About Us

Our Focus

Pipeline

Partnership

Investors

News

Careers

翌日披露报表 - 股份购回
2025-12-03
截至二零二五年十一月三十日止月份之股份发行人的证券变动月报表
2025-12-02
自愿性公告 - 歌礼选定其首款口服GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37进行临床开发
2025-11-30
自愿性公告 - 歌礼宣布每月一次新一代胰淀素受体激动剂ASC36和每月一次新一代GLP-1R/GIPR双靶点激动剂ASC35的复方制剂进入临床开发阶段
2025-11-13
翌日披露报表 - 股份购回
2025-11-05
自愿性公告 - 歌礼在2025年肥胖周（ObesityWeek®）报告ASC30口服片Ib期研究的完整分析、ASC30注射剂Ib期研究以及ASC31与ASC47联合用药临床前研究
2025-11-05
截至二零二五年十月三十一日止月份之股份发行人的证券变动月报表
2025-11-04
ASC36, a Once-Monthly Next-Generation Amylin Receptor Agonist Peptide, demonstrated 32-day average observed half-life, 6-fold longer than petrelintide, in NHP model and 91% more relative weight loss than petrelintide in DIO rat model
2026-05-14
ASC35, a Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist Peptide, demonstrated 14-day average observed half-life, 6-fold longer than tirzepatide, in NHP model and 71% more relative weight loss than tirzepatide in DIO mouse model
2026-05-14
翌日披露报表 - 股份购回
2025-10-31

5

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1